Publications
Found 2 results
Filters: Author is C.M. Willis [Clear All Filters]
“Elimination of breast tumor-associated chondroitin sulfate promotes metastasis”, vol. 10, pp. 3901-3913, 2011.
,
Alini M and Losa GA (1991). Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res. 51: 1443-1447.
PMid:1997183
Basappa MS, Sugahara KN, Lee CM, ten Dam GB, et al. (2009). Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19: 735-742.
http://dx.doi.org/10.1093/glycob/cwp041
PMid:19293233
Bradbury EJ and Carter LM (2011). Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res. Bull. 84: 306-316.
http://dx.doi.org/10.1016/j.brainresbull.2010.06.015
PMid:20620201
Cafferty WBJ, Yang SH, Duffy PJ, Li S, et al. (2007). Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J. Neurosci. 27: 2176-2185.
http://dx.doi.org/10.1523/JNEUROSCI.5176-06.2007
PMid:17329414 PMCid:2848955
Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, et al. (2011). Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 13: R58.
http://dx.doi.org/10.1186/bcr2895
PMid:21658254 PMCid:3218947
Coulson-Thomas YM, Coulson-Thomas VJ, Filippo TR, Mortara RA, et al. (2008). Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation. J. Neurosci. Methods 171: 19-29.
http://dx.doi.org/10.1016/j.jneumeth.2008.01.030
PMid:18417222
Habuchi O (2000). Diversity and functions of glycosaminoglycan sulfotransferases. Biochim. Biophys. Acta 1474: 115-127.
http://dx.doi.org/10.1016/S0304-4165(00)00016-7
Heinegard D (2009). Proteoglycans and more - from molecules to biology. Int. J. Exp. Pathol. 90: 575-586.
http://dx.doi.org/10.1111/j.1365-2613.2009.00695.x
PMid:19958398 PMCid:2803248
Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, et al. (2003). Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N. Y. Acad. Sci. 995: 151-161.
http://dx.doi.org/10.1111/j.1749-6632.2003.tb03218.x
PMid:12814947
Hendrix MJ, Seftor EA, Seftor REB, Kasemeier-Kulesa J, et al. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7: 246-255.
http://dx.doi.org/10.1038/nrc2108
PMid:17384580
Hochberg MC (2010). Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 18 (Suppl 1): S28-S31.
http://dx.doi.org/10.1016/j.joca.2010.02.016
PMid:20399895
Hogan BV, Peter MB, Shenoy H, Horgan K, et al. (2010). Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surg. Oncol. 19: 11-16.
http://dx.doi.org/10.1016/j.suronc.2008.12.009
PMid:19171479
Iida J, Wilhelmson KL, Ng J, Lee P, et al. (2007). Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem. J. 403: 553-563.
http://dx.doi.org/10.1042/BJ20061176
PMid:17217338 PMCid:1876388
Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, et al. (2009). Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional studies. Oncol. Rep. 22: 369-375.
PMid:19578779
Kawashima H, Hirose M, Hirose J, Nagakubo D, et al. (2000). Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J. Biol. Chem. 275: 35448-35456.
http://dx.doi.org/10.1074/jbc.M003387200
PMid:10950950
Kawashima H, Atarashi K, Hirose M, Hirose J, et al. (2002). Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J. Biol. Chem. 277: 12921-12930.
http://dx.doi.org/10.1074/jbc.M200396200
PMid:11821431
Kenny PA, Lee GY and Bissell MJ (2007). Targeting the tumor microenvironment. Front Biosci. 12: 3468-3474.
http://dx.doi.org/10.2741/2327
PMid:17485314 PMCid:2841020
Kim IS and Baek SH (2010). Mouse models for breast cancer metastasis. Biochem. Biophys. Res. Commun. 394: 443-447.
http://dx.doi.org/10.1016/j.bbrc.2010.03.070
PMid:20230796
Klüppel M (2010). The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog. Mol. Biol. Transl. Sci. 93: 113-132.
http://dx.doi.org/10.1016/S1877-1173(10)93006-8
Klüppel M (2011). Efficient secretion of biologically active Chondroitinase ABC from mammalian cells in the absence of an N-terminal signal peptide. Mol. Cell Biochem. 351: 1-11.
http://dx.doi.org/10.1007/s11010-010-0705-1
PMid:21213020
Klüppel M, Vallis KA and Wrana JL (2002). A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling. Mech. Dev. 118: 77-89.
http://dx.doi.org/10.1016/S0925-4773(02)00198-3
Klüppel M, Wight TN, Chan C, Hinek A, et al. (2005). Maintenance of chondroitin sulfation balance by chondroitin- 4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 132: 3989-4003.
http://dx.doi.org/10.1242/dev.01948
PMid:16079159
Kovalszky I, Pogany G, Molnar G, Jeney A, et al. (1990). Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem. Biophys. Res. Commun. 167: 883-890.
http://dx.doi.org/10.1016/0006-291X(90)90606-N
Krasnokutsky S, Samuels J and Abramson SB (2007). Osteoarthritis in 2007. Bull. NYU Hosp. Jt. Dis. 65: 222-228.
PMid:17922674
Kusche-Gullberg M and Kjellen L (2003). Sulfotransferases in glycosaminoglycan biosynthesis. Curr. Opin. Struct. Biol. 13: 605-611.
http://dx.doi.org/10.1016/j.sbi.2003.08.002
PMid:14568616
LaBarge MA, Petersen OW and Bissell MJ (2007). Of microenvironments and mammary stem cells. Stem. Cell Rev. 3: 137-146.
http://dx.doi.org/10.1007/s12015-007-0024-4
PMid:17873346 PMCid:3004778
Li F, Ten Dam GB, Murugan S, Yamada S, et al. (2008). Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J. Biol. Chem. 283: 34294-34304.
http://dx.doi.org/10.1074/jbc.M806015200
PMid:18930920 PMCid:2662238
Luo J, Kato M, Wang H, Bernfield M, et al. (2001). Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J. Cell Biochem. 80: 522-531.
http://dx.doi.org/10.1002/1097-4644(20010315)80:4<522::AID-JCB1006>3.0.CO;2-H
Mego M, Mani SA and Cristofanilli M (2010). Molecular mechanisms of metastasis in breast cancer - clinical applications. Nat. Rev. Clin. Oncol. 7: 693-701.
http://dx.doi.org/10.1038/nrclinonc.2010.171
PMid:20956980
Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, et al. (2007). Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int. J. Cancer 120: 1179-1191.
http://dx.doi.org/10.1002/ijc.22424
PMid:17154173
Mueller MM and Fusenig NE (2004). Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-849.
http://dx.doi.org/10.1038/nrc1477
PMid:15516957
Olsen EB, Trier K, Eldov K and Ammitzboll T (1988). Glycosaminoglycans in human breast cancer. Acta Obstet. Gynecol. Scand. 67: 539-542.
http://dx.doi.org/10.3109/00016348809029866
PMid:3239385
Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, et al. (2006). Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J. Biochem. 140: 517-524.
http://dx.doi.org/10.1093/jb/mvj181
PMid:16936295
Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, et al. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 3: 983-992.
PMid:9815775
Ricciardelli C, Quinn DI, Raymond WA, McCaul K, et al. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 59: 2324-2328.
PMid:10344737
Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, et al. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 69: 761-769.
http://dx.doi.org/10.1002/pros.20926
PMid:19189303
Sakko AJ, Butler MS, Byers S, Reinboth BJ, et al. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol. Biomark. Prev. 17: 2488-2497.
http://dx.doi.org/10.1158/1055-9965.EPI-08-0204
PMid:18768520
Suwiwat S, Ricciardelli C, Tammi R, Tammi M, et al. (2004). Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 10: 2491-2498.
http://dx.doi.org/10.1158/1078-0432.CCR-03-0146
PMid:15073129
Teng YH, Tan PH, Chia SJ, Zam NA, et al. (2008). Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod. Pathol. 21: 893-901.
http://dx.doi.org/10.1038/modpathol.2008.70
PMid:18487997
Thiele H, Sakano M, Kitagawa H, Sugahara K, et al. (2004). Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement. Proc. Natl. Acad. Sci. U. S. A. 101: 10155-10160.
http://dx.doi.org/10.1073/pnas.0400334101
PMid:15215498 PMCid:454181
Uebelhart D (2008). Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 16 (Suppl 3): S19-S21.
http://dx.doi.org/10.1016/j.joca.2008.06.006
PMid:18674931
Vijayagopal P, Figueroa JE and Levine EA (1998). Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J. Surg. Oncol. 68: 250-254.
http://dx.doi.org/10.1002/(SICI)1096-9098(199808)68:4<250::AID-JSO9>3.0.CO;2-3
Viloria-Petit AM and Wrana JL (2010). The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle 9: 623-624.
http://dx.doi.org/10.4161/cc.9.4.10779
PMid:20107326
Viloria-Petit AM, David L, Jia JY, Erdemir T, et al. (2009). A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106: 14028-14033.
http://dx.doi.org/10.1073/pnas.0906796106
PMid:19667198 PMCid:2729014
Wandel S, Juni P, Tendal B, Nuesch E, et al. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341: c4675.
http://dx.doi.org/10.1136/bmj.c4675
PMid:20847017 PMCid:2941572
Wegrowski Y and Maquart FX (2004). Involvement of stromal proteoglycans in tumour progression. Crit. Rev. Oncol. Hematol. 49: 259-268.
http://dx.doi.org/10.1016/j.critrevonc.2003.10.005
PMid:15036265
,